Skip to content

R&D at other companies

eXoZymes Inc. Common Stock logo
eXoZymes Inc. Common StockEXOZ
$1.12M+95.0%
Abbott logo
AbbottABT
$767M+7.1%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$3.89M-20.4%
John B. Sanfilippo & Son logo
John B. Sanfilippo & SonJBSS
$873.25K-3.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$10.6M+0.3%

Segments

By segment

See full
Consumer Products segment$733K+13.6%
Pharmaceuticals segment$368K
Ingredients segment$280K+14.3%
Analytical Reference Standards and Services segment$0

Other financials

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation

See full
Market cap$254.07M-74.9%
Enterprise value$190.09M-79.7%
P/E13.6×-43.5×
P/S-6.8×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp
FCF margin-70.4%

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0.0×
Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NAGE's R&D?
NAGE (NAGE) reported R&D of $1.48M in Q1 2026.
How has NAGE's R&D changed year-over-year?
NAGE's R&D increased by 17.7% year-over-year, from $1.26M to $1.48M.
What is the long-term trend for NAGE's R&D?
Over 3 years (2021 to 2025), NAGE's R&D has grown at a 18.2% compound annual growth rate (CAGR), from $3.83M to $6.33M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.